Sana Biotechnology (SANA) director granted 6,157 fully vested shares

Rhea-AI Filing Summary

Sana Biotechnology director Hans Edgar Bishop reported an equity award. On January 5, 2026, he acquired 6,157 shares of Common Stock in a transaction coded "A" for acquisition. The footnote explains these consist of fully vested restricted stock units, with a reported price of $0.00 per share, indicating no cash purchase. After this grant, Bishop is shown as beneficially owning 5,840,740 shares of Sana Biotechnology common stock in direct ownership.

Insider Trade Summary

Net Buyer: 6,157 shares

Net Buy 1 txn

Insider Bishop Hans Edgar

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,157	$0.00	$0.00

Holdings After Transaction: Common Stock — 5,840,740 shares (Direct)

Footnotes (1)

1. F1. Consists of fully vested restricted stock units.

FAQ

What insider transaction did Sana Biotechnology (SANA) report for Hans Edgar Bishop?

The filing reports that director Hans Edgar Bishop acquired 6,157 shares of Common Stock on January 5, 2026 in a transaction coded as an acquisition.

How were the 6,157 Sana Biotechnology (SANA) shares characterized in the Form 4?

The 6,157 shares are described in a footnote as consisting of fully vested restricted stock units, indicating they were granted as equity compensation.

What price per share was reported for Hans Edgar Bishop’s Sana (SANA) stock grant?

The Form 4 lists a transaction price of $0.00 per share for the 6,157 Common Stock units, consistent with a non-cash equity award.

How many Sana Biotechnology (SANA) shares does Hans Edgar Bishop hold after this transaction?

Following the reported acquisition, Hans Edgar Bishop is shown as beneficially owning 5,840,740 shares of Sana Biotechnology Common Stock in direct ownership.

What is Hans Edgar Bishop’s relationship to Sana Biotechnology (SANA)?

Hans Edgar Bishop is identified in the filing as a director of Sana Biotechnology, Inc. and is not listed as an officer or 10% owner.

Was the Sana Biotechnology (SANA) Form 4 filed for one or multiple reporting persons?

The Form 4 indicates it is filed by one reporting person, namely Hans Edgar Bishop, with the signature provided by an attorney-in-fact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 01/06/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bishop Hans Edgar

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 400

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		A		6,157(1)	A	$0.00	5,840,740	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of fully vested restricted stock units.

Remarks:

Exhibit List: Ex. 24 - Power of Attorney

	/s/ Aaron M. Grossman, Attorney-in-Fact for Hans Edgar Bishop	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.